Familial aggregation of longevity in giant cell arteritis and polymyalgia rheumatica

被引:0
作者
Marcin Milchert
Marek Brzosko
机构
[1] Pomeranian Medical University in Szczecin,Department of Rheumatology, Internal Medicine, Geriatrics and Clinical Immunology
来源
Rheumatology International | 2020年 / 40卷
关键词
Longevity; Mortality; Giant cell arteritis; Polymyalgia rheumatica;
D O I
暂无
中图分类号
学科分类号
摘要
The long-term mortality in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) is unexpectedly decreased or at least not increased regardless of several mortality risk factors that these diseases share with other chronic immune-mediated rheumatic diseases. The genetic and immunological profile of PMR/GCA patients is unique, therefore, the hypothesis that this profile provides some survival advantage to PMR/GCA patients should be considered. The longevity is a phenomenon that was demonstrated to be familial. The familial aggregation of longevity can be studied by analysis of life expectancy in family members. Here we test the hypothesis of the aggregation of an increased longevity in the families of PMR/GCA patients. We compared the age of death of 358 parents of 179 PMR and GCA patients with corresponding data retrieved from 506 parents of 253 randomly collected age and sex-matched controls. The number of nonagenarian (≥ 90-year -old) mothers of PMR/GCA patients was significantly higher (OR = 2.34, 95%CI 1.11–11.95, p < 0.0005) vs controls. Both nonagenarian parents were found in 6 patients (3.35%) and none in the control cohort (OR = 8.77, 95%CI 2.26–405.10, p = 0.003). Our data suggest the familial aggregation of nonagenarians in PMR/GCA patients.
引用
收藏
页码:2071 / 2075
页数:4
相关论文
共 61 条
[1]  
Hill CL(2017)Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis Semin Arthritis Rheum 46 513-519
[2]  
Black RJ(2001)Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls Rheumatology 40 1238-1242
[3]  
Nossent JC(2015)Incidence and mortality rates of biopsy proven giant cell arteritis in southern Sweden Ann Rheum Dis 74 993-997
[4]  
Gran JT(1996)Long-term survival of patients with giant cell arteritis in the American college of rheumatology giant cell arteritis classification criteria cohort Am J Med 100 1936-320
[5]  
Myklebust G(2011)Mortality in patients with biopsy-proven giant cell arteritis: a South Australian population-based study J Rheumatol 38 22157-345
[6]  
Wilsgaard T(2019)Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides Rheumatol (Oxford) 58 313-364
[7]  
Mohammad AJ(1981)Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. a follow-up study on ninety patients treated with corticosteroids Acta Med Scand 209 337-742
[8]  
Nilsson JA(1986)Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study of 90 patients treated with corticosteroids Acta Med Scand 220 361-143
[9]  
Jacobsson LT(1997)Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality J Rheumatol 24 21716-1368
[10]  
Matteson EL(2002)Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden J Rheumatol 29 737-41